2024
Clinical Significance of Diffusion-Weighted Brain MRI Lesions After TAVR Results of a Patient-Level Pooled Analysis
Lansky A, Grubman D, Dwyer M, Zivadinov R, Parise H, Moses J, Shah T, Pietras C, Tirziu D, Gambone L, Leon M, Nazif T, Messé S. Clinical Significance of Diffusion-Weighted Brain MRI Lesions After TAVR Results of a Patient-Level Pooled Analysis. Journal Of The American College Of Cardiology 2024, 84: 712-722. PMID: 39142725, DOI: 10.1016/j.jacc.2024.05.055.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementClinical ischemic strokeAcute brain infarctionDW-MRIReceiver operating characteristicIschemic strokeTranscatheter aortic valve replacement resultBrain infarctionPatient-level pooled analysisC-statisticBrain MRI lesionsAcute ischemic brain injuryDiffusion-weighted magnetic resonance imagingAortic valve replacementIndividual lesion volumesCore laboratory analysisIschemic brain injuryPredicting ischemic strokeMagnetic resonance imagingStroke Prevention TrialMRI lesionsValve replacementDW-MRI acquisitionsPatient-level dataPooled analysis
2023
Predictors of Cerebral Embolic Debris During Transcatheter Aortic Valve Replacement: The SafePass 2 First-in-Human Study
Grubman D, Ahmad Y, Leipsic J, Blanke P, Pasupati S, Webster M, Nazif T, Parise H, Lansky A. Predictors of Cerebral Embolic Debris During Transcatheter Aortic Valve Replacement: The SafePass 2 First-in-Human Study. The American Journal Of Cardiology 2023, 207: 28-34. PMID: 37722198, DOI: 10.1016/j.amjcard.2023.08.137.Peer-Reviewed Original ResearchConceptsTranscatheter aortic valve replacementAortic valve replacementValve replacementAtrial fibrillationHuman studiesEmbolic protection device useHigh embolic riskPrimary end pointHigh-risk patientsIndependent core laboratorySelf-expanding valvesComputed tomography angiographyProtection device useCerebral embolizationCerebrovascular eventsEmbolic riskAcute thrombusEmbolic burdenAngiography featuresTechnical successTomography angiographyEmbolic debrisValve useCore laboratoryEnd point
2022
Coronary Orbital Atherectomy in Patients With Severe Aortic Stenosis.
Donatelle M, Agasthi P, Parise H, Igyarto Z, Martinsen B, Leon M, Beohar N. Coronary Orbital Atherectomy in Patients With Severe Aortic Stenosis. Journal Of Invasive Cardiology 2022, 34: e696-e700. PMID: 36200995.Peer-Reviewed Original ResearchConceptsSevere aortic stenosisNon-AS cohortAortic stenosisNon-AS patientsSuccessful stent placementOrbital atherectomyStent placementOA useHospital major adverse cardiovascular eventsSevere calcific coronary artery diseaseCalcific coronary artery diseaseConcomitant severe aortic stenosisMajor adverse cardiovascular eventsCoronary orbital atherectomyIdeal revascularization strategyAdverse cardiovascular eventsMount Sinai Medical CenterProspective randomized trialsGlomerular filtration rateCoronary artery diseaseSinai Medical CenterPaucity of dataAngiographic complicationsMACE rateCardiovascular eventsRandomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study)
Shishehbor MH, Zeller T, Werner M, Brodmann M, Parise H, Holden A, Lichtenberg M, Parikh SA, Kashyap VS, Pietras C, Tirziu D, Ardakani S, Beschorner U, Krishnan P, Niazi KA, Wali AU, Lansky AJ. Randomized Trial of Chocolate Touch Compared With Lutonix Drug-Coated Balloon in Femoropopliteal Lesions (Chocolate Touch Study). Circulation 2022, 145: 1645-1654. PMID: 35377157, DOI: 10.1161/circulationaha.122.059646.Peer-Reviewed Original ResearchConceptsLutonix drug-coated balloonDrug-coated balloonsEnd pointPrimary efficacy end pointPrimary safety end pointIndependent clinical events committeeIschemic rest painPrimary efficacy rateEfficacy end pointPrimary end pointSafety end pointClinical events committeeMajor adverse eventsRate of restenosisDrug-Coated BalloonNoninferiority end pointSafety event rateAverage lesion lengthMajor amputationPopliteal diseaseRest painBailout stentingEfficacy ratePrimary patencyAdverse events
2016
Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial
Costa R, Abizaid A, Mehran R, Schofer J, Schuler G, Hauptmann K, Magalhães M, Parise H, Grube E, Investigators B. Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial. JACC Cardiovascular Interventions 2016, 9: 51-64. PMID: 26762911, DOI: 10.1016/j.jcin.2015.09.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiovascular AgentsCoronary AngiographyCoronary Artery DiseaseCoronary VesselsDrug-Eluting StentsFemaleGermanyHumansKaplan-Meier EstimateMaleMiddle AgedNeointimaPaclitaxelPercutaneous Coronary InterventionPredictive Value of TestsProspective StudiesProsthesis DesignRisk FactorsSingle-Blind MethodSirolimusStainless SteelSurface PropertiesTime FactorsTreatment OutcomeConceptsStent late lumen lossPaclitaxel-eluting stentsLate lumen lossDrug-coated stentsStent thrombosisBiolimus A9First-generation paclitaxel-eluting stentsDe novo coronary lesionsMajor adverse cardiac eventsPolymer-free biolimus A9Probable stent thrombosisAdverse cardiac eventsNovo coronary lesionsTarget lesion revascularizationClinical event ratesLong-term outcomesLesion revascularizationAngiographic followCardiac eventsClinical outcomesCoronary lesionsLesions 4Lumen lossStandard doseStainless steel platform
2014
Clinical and Angiographic Evaluation of the Resolute Zotarolimus-Eluting Coronary Stent in Japanese Patients
Saito S, Maehara A, Vlachojannis G, Parise H, Mehran R. Clinical and Angiographic Evaluation of the Resolute Zotarolimus-Eluting Coronary Stent in Japanese Patients. Circulation Journal 2014, 79: 96. PMID: 25428602, DOI: 10.1253/circj.cj-14-0836.Peer-Reviewed Original ResearchMeSH KeywordsCombined Modality TherapyCoronary AngiographyCoronary RestenosisCoronary StenosisDrug-Eluting StentsHeart DiseasesHumansIncidenceJapanMyocardial InfarctionMyocardial RevascularizationNeointimaPlatelet Aggregation InhibitorsPostoperative ComplicationsProspective StudiesRisk FactorsSirolimusTreatment OutcomeUltrasonography, InterventionalConceptsTarget lesion revascularizationJapanese patientsR-ZESDe novo native coronary lesionsIncidence of TLRSingle-arm observational studyStent late lumen lossLong-term clinical outcomesNative coronary lesionsTarget lesion failureLate lumen lossLesion revascularizationResolute ZotarolimusLesion failureVolume obstructionAngiographic evaluationClinical outcomesCoronary lesionsLumen lossObservational studyNeointimal hyperplasiaIntravascular ultrasoundPatientsVessel studiesCoronary stentsImpact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes Mellitus Analysis From 18 Pooled Randomized Trials
Kedhi E, Généreux P, Palmerini T, McAndrew T, Parise H, Mehran R, Dangas G, Stone G. Impact of Coronary Lesion Complexity on Drug-Eluting Stent Outcomes in Patients With and Without Diabetes Mellitus Analysis From 18 Pooled Randomized Trials. Journal Of The American College Of Cardiology 2014, 63: 2111-2118. PMID: 24632279, DOI: 10.1016/j.jacc.2014.01.064.Peer-Reviewed Original ResearchConceptsDiabetes mellitusRepeat revascularizationMyocardial infarctionLesion complexityStent outcomesCardiac deathType A/B1 lesionsType B2/C lesionsB2/C lesionsPropensity score-matched groupsCoronary lesion complexityTarget vessel revascularizationPatient-level dataB1 lesionsNoncomplex lesionsVessel revascularizationDiabetic statusC lesionsDES eraRandomized trialsRisk factorsTarget lesionsDES safetyTreatment outcomesBaseline differences
2013
Impact of Bivalirudin and Paclitaxel-Eluting Stents on Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention of the Left Anterior Descending Artery
Wöhrle J, Brodie B, Witzenbichler B, Dudek D, Kornowski R, Metzger C, Grines C, McAndrew T, Parise H, Sergie Z, Mehran R, Stone G. Impact of Bivalirudin and Paclitaxel-Eluting Stents on Outcomes in Patients Undergoing Primary Percutaneous Coronary Intervention of the Left Anterior Descending Artery. The American Journal Of Cardiology 2013, 112: 753-760. PMID: 23746479, DOI: 10.1016/j.amjcard.2013.05.006.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntineoplastic Agents, PhytogenicAntithrombinsCoronary AngiographyCoronary VesselsDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesHirudinsHumansMaleMiddle AgedMyocardial InfarctionPaclitaxelPeptide FragmentsPercutaneous Coronary InterventionProspective StudiesRecombinant ProteinsTreatment OutcomeConceptsPrimary percutaneous coronary interventionST-elevation myocardial infarctionPaclitaxel-eluting stentingImpact of bivalirudinTarget vessel revascularizationPercutaneous coronary interventionVessel revascularizationCoronary interventionCardiac deathPrimary PCIGlycoprotein IIb/IIIa inhibitorsIschemia-driven target vessel revascularizationIIb/IIIa inhibitorsLeft anterior descending (LAD) arteryHORIZONS-AMI trialMajor bleeding eventsUse of bivalirudinAnterior descending (LAD) arteryElevation myocardial infarctionBare-metal stentingSignificant lower rateLower ratesBleeding eventsCardiovascular eventsRevascularization rates
2012
Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials.
Kedhi E, Stone G, Kereiakes D, Serruys P, Parise H, Fahy M, Simonton C, Sudhir K, Sood P, Smits P. Stent thrombosis: insights on outcomes, predictors and impact of dual antiplatelet therapy interruption from the SPIRIT II, SPIRIT III, SPIRIT IV and COMPARE trials. EuroIntervention 2012, 8: 599-606. PMID: 22995087, DOI: 10.4244/eijv8i5a92.Peer-Reviewed Original ResearchConceptsDAPT discontinuationCardiac deathSPIRIT IIST ratesDual antiplatelet therapy discontinuationDual antiplatelet therapy interruptionSPIRIT IIIAntiplatelet therapy discontinuationAntiplatelet therapy interruptionLarge pooled analysisRandomised clinical trialsTwo-year ratePatient-level databaseLog-rank testPES cohortTherapy discontinuationTherapy interruptionRandomised trialsStent thrombosisPaclitaxel-eluting stent deploymentPooled analysisClinical trialsDiscontinuationStent deploymentComposite rateImpact of major bleeding and blood transfusions after cardiac surgery: Analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial
Stone G, Clayton T, Mehran R, Dangas G, Parise H, Fahy M, Pocock S. Impact of major bleeding and blood transfusions after cardiac surgery: Analysis from the Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial. American Heart Journal 2012, 163: 522-529. PMID: 22424026, DOI: 10.1016/j.ahj.2011.11.016.Peer-Reviewed Original ResearchConceptsRed blood cell transfusionAcute coronary syndromeBlood cell transfusionMajor bleedingRBC transfusionCell transfusionCoronary syndromeCardiac surgerySubsequent mortalityUrgent Intervention Triage Strategy (ACUITY) trialAllogeneic blood product transfusionInternational prospective trialsCoronary artery bypassMajor hemorrhagic complicationsOne-year mortalityBlood product transfusionCovariate-adjusted Cox modelsPrior retrospective studiesFresh frozen plasmaAcute CatheterizationArtery bypassHemorrhagic complicationsProduct transfusionHospital dischargeProspective trial
2011
Impact of Diabetes Mellitus on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty Analysis From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial
Witzenbichler B, Mehran R, Guagliumi G, Dudek D, Huber K, Kornowski R, Stuckey T, Fahy M, Parise H, Stone G. Impact of Diabetes Mellitus on the Safety and Effectiveness of Bivalirudin in Patients With Acute Myocardial Infarction Undergoing Primary Angioplasty Analysis From the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) Trial. JACC Cardiovascular Interventions 2011, 4: 760-768. PMID: 21777884, DOI: 10.1016/j.jcin.2011.04.008.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAntithrombinsCoronary AngiographyDiabetes MellitusDose-Response Relationship, DrugDouble-Blind MethodElectrocardiographyFemaleFollow-Up StudiesHirudinsHumansHypoglycemic AgentsMaleMiddle AgedMyocardial InfarctionPeptide FragmentsProspective StudiesRecombinant ProteinsStentsSurvival RateTime FactorsTreatment OutcomeConceptsGlycoprotein IIb/IIIa inhibitorsST-segment elevation myocardial infarctionPrimary percutaneous coronary interventionHORIZONS-AMI trialDiabetes mellitusDiabetic patientsMyocardial infarctionPrimary PCIMajor adverse cardiac eventsIIb/IIIa inhibitorsEffectiveness of bivalirudinEfficacy of bivalirudinAdverse cardiac eventsAcute coronary syndromeElevation myocardial infarctionPercutaneous coronary interventionAcute myocardial infarctionMajor bleedingCardiac mortalityCoronary syndromeAnticoagulant therapyCardiac eventsCoronary interventionCardiac deathUnfractionated heparinHeparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial
Stone G, Witzenbichler B, Guagliumi G, Peruga J, Brodie B, Dudek D, Kornowski R, Hartmann F, Gersh B, Pocock S, Dangas G, Wong S, Fahy M, Parise H, Mehran R, Investigators O. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. The Lancet 2011, 377: 2193-2204. PMID: 21665265, DOI: 10.1016/s0140-6736(11)60764-2.Peer-Reviewed Original ResearchMeSH KeywordsAngioplasty, BalloonCombined Modality TherapyConfidence IntervalsDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationDrug-Eluting StentsElectrocardiographyFemaleFollow-Up StudiesHeparinHirudinsHumansKaplan-Meier EstimateMaleMyocardial InfarctionPaclitaxelPeptide FragmentsPlatelet Glycoprotein GPIIb-IIIa ComplexProspective StudiesRecombinant ProteinsStentsSurvival AnalysisTime FactorsTreatment OutcomeConceptsST-segment elevation myocardial infarctionGlycoprotein IIb/IIIa inhibitorsPrimary percutaneous coronary interventionIIb/IIIa inhibitorsPercutaneous coronary interventionPaclitaxel-eluting stentsBare metal stentsBivalirudin monotherapyStent thrombosisCoronary interventionMyocardial infarctionIschaemia-driven target lesion revascularisationIschaemia-driven target vessel revascularisationMajor adverse cardiovascular eventsComposite adverse eventsHORIZONS-AMI trialPaclitaxel-eluting stentingTarget vessel revascularisationAdverse cardiovascular eventsBypass graft surgeryTarget lesion revascularisationElevation myocardial infarctionOnset of symptomsKaplan-Meier estimatesAcute myocardial infarctionPredictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials.
Kereiakes D, Smits P, Kedhi E, Parise H, Fahy M, Serruys P, Stone G. Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials. EuroIntervention 2011, 7: 74-83. PMID: 21550906, DOI: 10.4244/eijv7i1a14.Peer-Reviewed Original ResearchConceptsMajor adverse cardiovascular eventsAdverse cardiovascular eventsPaclitaxel-eluting stentsMyocardial infarctionIndependent predictorsID-TLRID-TVRCardiac deathCardiovascular eventsSPIRIT IIStent deploymentDrug-eluting stent deploymentPredictors of deathAdverse clinical outcomesCoronary artery diseaseSuperior clinical efficacyIschaemia-driven revascularisationNumber of lesionsArtery diseaseCoronary stentingClinical outcomesClinical efficacyAdverse outcomesPaclitaxel-eluting stent deploymentClinical trials
2010
Impact of Transfer for Primary Percutaneous Coronary Intervention on Survival and Clinical Outcomes (from the HORIZONS-AMI Trial)
Wöhrle J, Desaga M, Metzger C, Huber K, Suryapranata H, Guetta V, Guagliumi G, Witzenbichler B, Parise H, Mehran R, Stone G. Impact of Transfer for Primary Percutaneous Coronary Intervention on Survival and Clinical Outcomes (from the HORIZONS-AMI Trial). The American Journal Of Cardiology 2010, 106: 1218-1224. PMID: 21029816, DOI: 10.1016/j.amjcard.2010.06.049.Peer-Reviewed Original ResearchMeSH KeywordsAgedAngioplasty, Balloon, CoronaryAnticoagulantsChi-Square DistributionCoronary AngiographyFemaleHeparinHirudinsHumansMaleMiddle AgedMyocardial InfarctionPatient TransferPeptide FragmentsProportional Hazards ModelsProspective StudiesRecombinant ProteinsStatistics, NonparametricSurvival RateTime FactorsTreatment OutcomeConceptsPrimary percutaneous coronary interventionPrimary PCIST-segment elevation myocardial infarctionHORIZONS-AMI trialPercutaneous coronary interventionClinical outcomesCoronary interventionGlycoprotein IIb/IIIa inhibitorsMajor adverse cardiac eventsNet adverse clinical eventsIIb/IIIa inhibitorsAdverse cardiac eventsAdverse clinical eventsElevation myocardial infarctionPreferred reperfusion strategyPresentation of patientsInterventional hospitalMajor bleedingReperfusion strategyBalloon timeCardiac eventsCardiac deathPCI centerUnfractionated heparinMedian time
2007
Pulse Pressure and Risk of New-Onset Atrial Fibrillation
Mitchell G, Vasan R, Keyes M, Parise H, Wang T, Larson M, D’Agostino R, Kannel W, Levy D, Benjamin E. Pulse Pressure and Risk of New-Onset Atrial Fibrillation. JAMA 2007, 297: 709-715. PMID: 17312290, DOI: 10.1001/jama.297.7.709.Peer-Reviewed Original ResearchConceptsIncident atrial fibrillationMean arterial pressureAtrial fibrillationPulse pressureRisk factorsArterial pressureCommunity-based observational cohortNew-onset atrial fibrillationIncidence of AFAF incidence ratesClinical risk factorsModifiable risk factorsVentricular fractional shorteningFramingham Heart Study participantsImportant risk factorCommunity-based sampleAtrial dimensionObservational cohortAortic stiffnessConsiderable morbidityFractional shorteningSystolic pressureAF riskDiastolic pressureVentricular mass
2005
Cross-Sectional Association of Kidney Function with Valvular and Annular Calcification: The Framingham Heart Study
Fox C, Larson M, Vasan R, Guo C, Parise H, Levy D, Leip E, O’Donnell C, D’Agostino R, Benjamin E. Cross-Sectional Association of Kidney Function with Valvular and Annular Calcification: The Framingham Heart Study. Journal Of The American Society Of Nephrology 2005, 17: 521-527. PMID: 16382018, DOI: 10.1681/asn.2005060627.Peer-Reviewed Original ResearchConceptsMitral annular calcificationAortic annular calcificationAnnular calcificationValvular calcificationKidney diseaseAortic sclerosisKidney functionPresence of MACTotal/HDL cholesterolVascular risk factor burdenRenal Disease Study equationEnd-stage kidney diseaseRisk factor burdenCardiovascular risk factorsCardiovascular disease eventsChronic kidney diseaseEarly kidney diseaseBody mass indexOnset of ESRDFramingham Offspring StudyTwo-dimensional echocardiographyFramingham Heart StudyDiastolic BPHDL cholesterolHypertension treatment
2004
Parental Atrial Fibrillation as a Risk Factor for Atrial Fibrillation in Offspring
Fox C, Parise H, D'Agostino R, Lloyd-Jones D, Vasan R, Wang T, Levy D, Wolf P, Benjamin E. Parental Atrial Fibrillation as a Risk Factor for Atrial Fibrillation in Offspring. JAMA 2004, 291: 2851-2855. PMID: 15199036, DOI: 10.1001/jama.291.23.2851.Peer-Reviewed Original ResearchMeSH KeywordsAdultAdult ChildrenAgedAtrial FibrillationFemaleHumansMaleMiddle AgedProspective StudiesRisk FactorsConceptsAtrial fibrillationOffspring participantsNew-onset atrial fibrillationPopulation-based epidemiologic studyAntecedent myocardial infarctionCommon cardiac dysrhythmiaProspective cohort studyYears of ageFramingham Heart StudyFamilial atrial fibrillationCohort studyHeart failureCardiac dysrhythmiasMyocardial infarctionOriginal cohortRisk factorsEpidemiologic studiesRare caseHeart StudyGenetic susceptibilityFibrillationUnselected individualsGenetic factorsDysrhythmiasFuture risk
2002
Overweight and Obesity as Determinants of Cardiovascular Risk: The Framingham Experience
Wilson P, D'Agostino R, Sullivan L, Parise H, Kannel W. Overweight and Obesity as Determinants of Cardiovascular Risk: The Framingham Experience. JAMA Internal Medicine 2002, 162: 1867-1872. PMID: 12196085, DOI: 10.1001/archinte.162.16.1867.Peer-Reviewed Original ResearchConceptsAge-adjusted relative riskBody mass indexCoronary heart diseasePopulation attributable riskRelative riskCardiovascular diseaseCardiovascular sequelaeAngina pectorisExcess weightAttributable riskHeart diseaseOverweight statusRisk factorsCardiovascular disease risk factorsHighest population-attributable riskNew cardiovascular diseaseDisease risk factorsFramingham Heart Study participantsNormal-weight personsDisease end pointsNew hypertensionCardiovascular riskDiabetes mellitusPrimary outcomeMass index